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ABSTRACT
Objectives: The aim of the study was to explore
women’s motivations for participating in a clinical trial
and to evaluate how financial compensation impacts
women’s explanations for participation.
Design, setting and participants: Semistructured
interviews were conducted face to face or by telephone
with 25 of 220 women who participated in a pragmatic
randomised trial for app-administered self-care
acupressure for dysmenorrhoea (AKUD). Of these 25
women, 10 had entered AKUD knowing they would
receive a financial compensation of €30. A purposive
sampling strategy was used.
Results: Women had a long history of seeking help
and were unsatisfied with the options available, namely
painkillers and oral contraceptives. While interviewees
were open to painkillers, they were uneasy about taking
them on a monthly basis. The AKUD trial offered the
possibility to find an alternative solution. A second
reason for participation was the desire to add a new
treatment to routine medical care, for which the
interviewees considered randomised trials a
prerequisite. The financial incentive was a subsidiary
motivation in the interviewees’ narratives.
Conclusions: Our results contribute to the ongoing
discussion of the impact of financial compensation on
research participants’ assessment of risk. The
interviewed women considered all research participants
able to make their own choices regarding trial
participation, even in the face of financial
compensation or payment of study participants.
Furthermore, the importance of clinical trials providing
new treatments that could change medical practice
might be an overlooked reason for trial participation
and could be used in future recruitment strategies.
INTRODUCTION
Randomised clinical trials are seen as the
gold standard in clinical research, yet their
success depends on the willingness of people
to volunteer. Poor recruitment for clinical
studies impacts statistical power, internal and
external validity and can cause ﬁnancial and
practical restrictions.1 Recruitment problems
are a common obstacle in clinical studies2 3
and numerous strategies have been identiﬁed
to improve recruitment, including pro-
grammes to increase potential participants’
awareness of a health problem and its pos-
sible impact on them,4 making telephone
contact with potential participants and using
opt-out rather than opt-in procedures.5
Campbell et al6 found that certain factors
proved successful in recruitment, including
having a dedicated trial manager, it being a
cancer drug trial and having interventions
only available within the trial. Thus, both
trial characteristics and communication strat-
egies with potential participants are of
importance for recruitment.
The payment of research participants has
also been shown to increase participation.7
Such a strategy is controversial, however, as it
may inﬂuence individuals’ informed
decision-making.5 In particular, it is argued
that payment may unduly inﬂuence socio-
economically disadvantaged populations8
and could jeopardise informed consent and
participants’ autonomous ability to properly
assess risks and beneﬁts.9 10 Indeed, studies
have shown that higher compensation
increases willingness to participate and that
Strengths and limitations of this study
▪ The special setting of our study that included
women who had entered the clinical trial both
knowing and not knowing that they would
receive a financial compensation of €30 allowed
us to focus on the role of financial compensation
in the decision-making processes of women
when deciding on trial participation.
▪ The study contributes to understanding how
altruistic and personal reasons influence trial
participation.
▪ Sampling bias might have occurred because our
sample was predominantly highly educated,
including many with a medical background.
▪ Generalisability of our results is confined to
women unsatisfied with the solutions for men-
strual pain offered within the health system.
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participants will assume higher risks when compensation
is high.11 12 It has been argued that whether it is ethical
to pay research participants depends on the purpose of
payment.8 Ethical concerns do not generally affect
studies with minimal risk of harm13 or those that reim-
burse only for time and travel expenses,9 but do arise
when payments exceed a certain threshold and/or com-
pensate for potential risk.
There exists a range of studies from the USA investi-
gating the participation of healthy volunteers in phase 1
clinical trials.14–17 Such trials investigate a treatment in
humans for the ﬁrst time to test the safety of a drug,
and are thus precarious in several ways and pose particu-
lar ethical problems. For instance, the risk of participa-
tion in trials is unknown and they require healthy
volunteers who will be very closely monitored and must
invest a large amount of their time. For this, participants
receive payment. Often, participants in phase 1 studies
include people in precarious ﬁnancial situations, who
may be serial study participants.14 15 18
To the best of our knowledge, only one study until
now has looked at research participants’ perspectives on
ﬁnancial compensation in phase 3 clinical trials—which
assess the effectiveness of a new intervention and its
value in clinical practice—with mixed results.19 Some of
the unpaid participants argued that compensation is a
valid recognition of participants; others clearly disagreed
with the idea of paid participation, arguing that it is a
moral duty. Altruism and the wish to beneﬁt others and
oneself have been identiﬁed as major reasons for partici-
pating in phase 3 clinical trials,20–24 though given the
evidence that communication strategies and trial
characteristics might also be important motivations, the
question arises of what altruism, moral duty and beneﬁt
to others actually imply. Indeed, it remains unclear how
ﬁnancial compensation actually inﬂuences participants’
willingness to enroll in research and what other factors
also play a role.
Trial for acupressure against menstrual pain (AKUD)
The randomised pragmatic trial AKUD25 was set up to
assess the effectiveness of self-acupressure supported by
a smartphone app (intervention), compared to usual
care (control group), for 220 women with menstrual
pain (trial registered at clinicaltrials.gov under
NCT01582724). All women received the AKUD app,
which provided questionnaires, diaries and, for the
women in the intervention group, guidance on self-
acupressure. The trial ran from December 2012 to April
2015. Women were recruited in Berlin, Germany from
December 2012 to August 2014 through posters and
ﬂyers at university campuses in Berlin, the intranet plat-
forms of Charité—Universitätsmedizin Berlin and adver-
tisements on two Berlin subway lines for 5 months.
Women in the intervention group were asked to apply
acupressure 5 days before the start of menstruation (1–2
times a day, 6 min per session) and on the days of pain
(up to 6 times a day). On completion of the study, the
acupressure features were activated on the app for the
women in the control group and those interested could
receive a personal introduction at the Institute for Social
Medicine, Epidemiology and Health Economics, Charité
—Universitätsmedizin.
To increase participation rates, the study group
decided after 8 months to introduce a ﬁnancial compen-
sation of €30 and to change the upper age limit for par-
ticipants from 25 to 34 years. We announced the
introduction of the ﬁnancial compensation, including
the amount, on the advertisements for the AKUD study.
On the more detailed AKUD information leaﬂet, we
added that after successful study participation, partici-
pants would receive a compensation of €30. Trial partici-
pants who had completed all questionnaires were
informed by email that they could collect their €30 at
the Institute (later on in the trial, the money was trans-
ferred to participants’ bank accounts). Women who par-
ticipated in AKUD before the ﬁnancial compensation
was introduced received the information about the com-
pensation at the latest on completion of the study.
As a result of these changes (ﬁnancial compensation,
change of age range), the monthly recruitment ﬁgures
for AKUD almost doubled (mean n=13.4 per month
after the changes compared to mean n=7 per month
before). Women who were interested in participating in
the study were invited to the Institute once for a screen-
ing and baseline visit (duration ∼30–60 min). All other
quantitative data were collected through the app with a
time requirement of 5–10 min per cycle.
The aim of this qualitative study was to analyse
women’s motivations for participating in the trial,
including whether the small ﬁnancial compensation had
an impact and to assess women’s general views on ﬁnan-
cial incentives for research participation.
METHODS
Design
This qualitative study was nested in the AKUD trial,25
and was conducted by the Institute for Social Medicine,
Epidemiology and Health Economics at the Charité—
Universitätsmedizin Berlin. Qualitative, semi-structured
interviews were conducted with trial participants after
they had completed all questionnaires for the AKUD
trial, in order to avoid inﬂuencing the results of AKUD.
Sampling and recruitment
Based on experience from other qualitative studies
nested in randomised clinical trials, a sample size of 20–
30 participants was aimed for.26–28 Recruitment for the
qualitative study took place between September 2013
and January 2015, with the selected participants invited
for an interview by mail or phone. Up to March 2014,
26 women in the intervention group and 23 women in
the control group were informed about the qualitative
study; this led to 21 interviews up to March 2014. The
sampling strategy was purposeful, with the sample
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selected based on whether the women had been
recruited to AKUD before or after ﬁnancial compensa-
tion had been introduced. The aim was to interview
more women (a minimum of 15) who had been
recruited prior to the introduction of the incentive, as
we assumed that their reasons would be more diverse
and would differ from those who participated after the
introduction of the incentive, for whom we assumed the
ﬁnancial incentive had played an important role.
In addition to the two groups ‘non-incentive’ and
‘incentive’, for our sampling strategy we further distin-
guished the women according to whether they had been
randomised to the intervention group or to the waiting
list (control group). We aimed for an equal distribution
across the intervention and control groups for the inter-
view sample.
Participants were invited to the qualitative study until
we had conducted 21 interviews. Those who were not
interested in an interview (∼24 women) mentioned time
constraints and no interest as reasons. We then analysed
the materials and resumed recruitment in March 2015,
adding another four interviewees to the sample to verify
the ﬁndings of the analysis and ensure data saturation.
Data collection
The ﬁrst 21 interviews took place at the Institute, while
the ﬁnal 4 interviews were conducted by phone. All
interviews were conducted only after written informed
consent had been provided by interviewees.
The interviews were semi-structured according to an
interview guide that had been developed based on the
research question, existing literature and discussion
within the study team (box 1). Additionally, sociodemo-
graphic information, pain intensity and medication use
were collected for all interviewees.
All interviews were conducted one-to-one by SB. All
authors are experienced qualitative researchers. SB
received training in qualitative interviewing from CH
and initial interviews were discussed by the research
team and in a qualitative research group at the Charité -
Universitätsmedizin Berlin with regard to interview tech-
niques and improvements in the interview guide. SB
was also responsible for the overall organisation of
the AKUD trial but had no contact with study partici-
pants and therefore did not know the interviewees
beforehand.
Analysis
After each interview, the interviewer wrote an interview
summary form29 that included interpersonal aspects of
the interviews as well as brief summaries for each
research question based on interviewees’ statements.
These interview summary forms were included in the
analysis to account for the relationship between the
interviewer and interviewee in data analysis.29 The inter-
views were digitally recorded and transcribed verbatim.
Transcripts were pseudonymised by changing the
women’s names. Transcripts were uploaded into the
software program MAXQDA (V.11 for Mac) and a the-
matic analysis of the transcripts was conducted.30
All interview material was coded by SB. The ﬁrst
round of coding was done based on the interview guide.
After this initial coding process to structure the data,
each coded segment was analysed for present themes
and coded accordingly. These two rounds of coding
were conducted by SB for the ﬁrst ﬁve interviews. The
resulting themes and the coding tree were discussed by
SB and CH and in a qualitative research group at the
Charité - Universitätsmedizin Berlin to ensure intersub-
jectivity and grounding in the analysis. The coding
process then continued for the ﬁrst 21 interviews. In this
process, major themes emerged that were discussed by
the research team. All analysis steps were documented
in written memos. After 21 interviews, analysis was con-
sidered complete as the same important themes contin-
ued to occur. Results were presented and discussed by
the research team. To verify the ﬁndings of the analysis,
four additional interviews were conducted, which pre-
sented the same themes and thus data collection was
terminated.
RESULTS
Sample
Twenty-ﬁve women were interviewed (duration 10–
50 min, mean 27 min), of whom 15 had been recruited
to AKUD without ﬁnancial incentive and 10 with ﬁnan-
cial incentive (table 1). The mean age of the women in
the non-incentive group was 22.7 years (range 21–25)
and in the incentive group 26.4 years (range 24–33).
The interviewees were mostly highly educated and
one-third mentioned having a medical background (eg,
medical student or working at the Charité—
Box 1 Interview guide
You have participated in the acupressure for dysmenorrhoea
(AKUD) trial, which investigated the effectiveness of acupressure
against menstrual pain.
Motivation for participation
What reasons did you have to participate?
Was the app a reason to participate?
Was the €30 a reason to participate?
Decision-making
How did you decide to participate?
Where did you hear about the study?
With whom, if anyone, have you discussed your study
participation?
Have you participated in other studies? If so, what was your
experience?
Do you have prior experience with acupressure or other com-
plementary therapies? If so, what was your experience?
Menstrual pain
How have you dealt with menstrual pain prior to the AKUD study?
How have you experienced menstrual pain in your daily life?
Opinion incentive
What is your view on payment of research participants?
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Universitätsmedizin Berlin). The majority (n=19) of
interviewees took painkillers for their menstrual pain,
with ibuprofen, aspirin and paracetamol being the most
common.
Thematic findings
Analysis of the interviews showed that in order to under-
stand women’s participation in the AKUD trial, an
understanding of their prior situation was important;
namely, they all routinely experienced a signiﬁcant
impact of menstrual pain on their lives. The women had
a history of searching for an appropriate solution and
were unsatisﬁed with the limited options offered to
them by their healthcare providers, namely painkillers
or the contraceptive pill. While interviewees were open
to painkillers, they were uneasy about taking them on a
monthly basis. Interviewees had an understanding that
randomised clinical trials are a necessary prerequisite to
introducing a new treatment option into medical care.
The ﬁnancial compensation received was seen as a nice
and appropriate bonus to their AKUD participation. We
describe below the aforementioned themes in detail.
While analysis was conducted separately for the incentive
and non-incentive groups, results were similar. The ﬁnd-
ings are thus presented jointly, except with regard to
ﬁnancial compensation.
Women’s situation prior to trial participation
All women described how menstruation pain impacted
their daily lives and disturbed their normal routines. For
some, taking analgesics or the oral contraceptives alle-
viated the pain enough to allow their activities to con-
tinue. Others discussed how the pain affected everything
—their social life, education, work—and was
all-encompassing while it endured; some had to stay in
bed and avoid all activities outside the house. Many
interviewees described increased pain in stress situations
and thus actively tried to reduce stress during menstru-
ation. Such coping strategies became problematic when
menstruation coincided with appointments that could
not be postponed, while cancellation of appointments
and work absences caused additional emotional stress
for some women. Sometimes, the pain also ruined key
planned events.
Yes, right, (…) menstrual pain is just stupid, it messes up
everything. It always comes when you have a birthday, or
Christmas or when something is…nice actually, and then
it’s always so annoying when…you just lie in bed the
whole time, or have to take a whole lot of painkillers
(Berta, non-incentive, intervention group).
All interviewed women, except for three, regularly
took analgesics to reduce their regular menstrual pain.
However, all continued to search for more satisfying
care. For example, of those who did not take analgesics
at all, two dealt with their pain by lying down with a hot
water bottle, while the third took contraceptive pills spe-
ciﬁcally to reduce her menstrual pain. For some intervie-
wees, although they took analgesics and oral
contraceptives, these medications were not effective in
reducing their pain or they had not tolerated the medi-
cation (n=4 non-incentive; n=4 incentive).
None of the interviewees were against medication in
general, though they did perceive it critically due to the
potential side effects. They also did not generally think
that complementary medicine is better than usual medi-
cine. Nevertheless, they shared a critical view on analge-
sics as a regular solution for menstrual pain. The
regularity and continuity of menstruation and the
related pain, as mentioned by ﬁve women (n=2 non-
incentive; n=3 incentive), made it difﬁcult to accept
analgesia as an appropriate solution.
So for me perhaps already the primary decisive reason
was…because I thought maybe it helps somehow. And
because it always bothered me that I have to take so
many painkillers. If once a month you always have to take
so many painkillers…actually I do not like the feeling
(Viola, incentive, intervention group).
Many of the participants had sought alternatives to
analgesics—including household remedies such as hot
water bottles and tea—but with limited success. Some
participants had tried, with mostly minimal effect, acu-
puncture, herbs, homeopathy, dancing/movement and
Table 1 Characteristics of the interviewees
Recruitment without
incentive
n=15
Recruitment with
incentive
n=10
Intervention
n=4
Control
n=11
Intervention
n=9
Control
n=1
Mean age (M, SD) 23.3±2.1 22.6±2.0 26.6±2.8 25
≥12 years of school education 3 11 9 1
Painkiller or hormonal contraceptive against menstruation pain 4 9 6 1
Mean pain intensity during last menstruation (NRS*: mean, SD) 5.0±2.2 5.3±1.7 5.8±1.6 7.0
Worst pain during last menstruation (NRS: M, SD) 7.5±1.0 7.0±1.3 6.9±0.9 8.0
*Numeric Rating Scale.
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gymnastics. Such experiences left the women feeling
alone with their symptoms and disillusioned with the
medical system that had too few options for treating
menstrual pain.
Deciding on the AKUD trial
Hope for relief with no added risk
The AKUD trial was seen as a possible solution for their
pain. The main reason for all interviewees for participa-
tion was to ﬁnd a new or additional means to deal with
their monthly ordeal.
So it’s as I said. I’m sick once a month and I ﬁnd that
quite a limitation given the fact that it’s [menstrual pain]
not a disease. … And I just hoped that something could
help. That I could just … cope with my everyday life. …
Because up to now there has been no solution (Zara,
incentive, intervention group).
For many interviewees, it was important that the AKUD
trial offered a non-drug therapy as a treatment option. As
a reason for participation, the interviewees stressed the
fact that they considered acupressure to be natural and
thus could do no harm, more than they cited the poten-
tial effectiveness that acupuncture may have. Therefore,
most of them had decided on participation spontaneously
while reading about the trial on posters at locations such
as the Charité - Universitätsmedizin Berlin or on ofﬁcial
advertisement bulletins in the subway system. They did
not talk to friends, family or physicians before making
the decision. Questions they may have had such as time
commitment were asked when they contacted the AKUD
study center.
Adding a treatment option to medical care
In addition to ﬁnding relief for their own monthly pain,
some interviewees clearly indicated that their participa-
tion could beneﬁt other women, as a positive evaluation
of acupressure would lead to more treatment options
that physicians could offer patients. Such ideas were
coupled with their belief that menstrual pain and dissat-
isfaction with current therapeutic options are an experi-
ence shared by many.
Women considered their study participation an
important part of building evidence for medical prac-
tice. They were also open to the procedure of random-
isation as a means to obtain valuable scientiﬁc evidence.
Interviewees likewise emphasised the importance of
informing gynaecologists of the results of the study, in
the hope of reaching as many women as possible.
Exactly, I also wish that it, acupressure, somehow turns
out to be a big success, and that it might be a real
option….So for me the study proved really meaningful
and you could say…okay, women have…such and such a
percentage somehow to thereby have an improvement or
so….And then you could, maybe you can actually publish
that and can say, okay…try this…(Mia, non-incentive,
control group).
App as a motivational technology
Interviewees found the app useful and convenient;
however, none considered it a reason for participation.
SB: And the app? Was that a motivation to take part in
the study?
Dora: Um, well a motivation, I don’t know, but I, it was
very convenient in any case (non-incentive, control
group).
Financial benefit
Although ﬁnancial gain could not have been a motiv-
ation for participation for the 15 women in the non-
incentive group, all of the women in both groups
expressed gratitude for the ﬁnancial compensation. The
majority agreed that ﬁnancial compensation to cover
transportation and time expenditure is appropriate for
the efforts of trial participation. Only two women in the
non-incentive group argued that the potential personal
beneﬁt outweighed any time expenditure and found
ﬁnancial compensation unnecessary.
Yes exactly. I see no reason, actually, no reason, uh, that
you pay us for it [participation]….Because…uh, the
people who participate gladly take the time for it and…
are not forced into it, so…I don’t know. For me it goes
without saying that when there is actually no money, that
it is not about money. Because, uh, you give us some-
thing. So we, we give our time, but we usually get a posi-
tive result, so … (Olga, non-incentive, control group).
Some women in the incentive group did argue that
ﬁnancial compensation had been a deciding factor for
participation (n=2). The majority of interviewees were
students or in vocational training, and they mentioned
the importance of a small subsidy to cover daily
expenses.
Thea: Um…on the other hand, even if, if it’s not much
money, it’s just still the thirty Euros that we as trainees,
we’re just…always at the limit anyway. Yes, still not a lot of
money and then doing it also for thirty Euros is also…a
triﬂe.
SB: Hmm, hmm. That was, so that was also something
extra, it was an added incentive.
Thea: Yes (incentive, intervention group).
Overall, interviewees believed that clinical trials are
necessary to improve medical practice. Thus, payment to
incentivise recruitment is also necessary, since without it
medical progress could be endangered.
Interviewees did not agree that compensation would
impair their judgement regarding a trial’s risks and ben-
eﬁts. They also argued that adults are capable of making
a judgement of the risks involved and deciding inde-
pendently what they are willing to undertake for a ﬁnan-
cial incentive. In addition, they agreed that the higher
the risk of a trial, the higher the compensation should
be. A few women mentioned that payment should not
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exceed compensation for travel costs and time, and
should not be the only reason for participation.
Yes, so I don’t know if one can say that very poor people
are forced to take part in some studies. That is, actually I
ﬁnd this not quite a correct statement, because I think
there is no one who tells people you have to participate
in this study. So I think it’s always an individual decision
that everyone can decide for himself whether he wants to
join a study or not (Ana, non-incentive, control group).
Hmm. But I think that…it would be difﬁcult to ﬁnd parti-
cipants at all….I think that’s always the problem….It’s just
always the question of how necessary it is…to do this
study….So I’m thinking: you must then weigh up, is it now
really…worth it, that it might also save people from harm,
…or uh, does it not have to be? But I think that since the
pharmaceutical industry also puts a lot of money into such
studies, they could also do it [offer ﬁnancial compensa-
tion] (Viola, incentive, intervention group).
DISCUSSION
In this study, we show that the alignment of a range of
factors and the characteristics of AKUD—offering a
desired-for intervention, dealing with menstrual pain
and that the intervention was viewed as harmless—were
decisive for trial participation. In particular, the trial
addressed a condition of importance to the women—
that is, a monthly ordeal for which the medical system
provides treatment options with which the women were
uneasy, and for which they hoped to add another thera-
peutic option through their trial participation. It is also
interesting that contrary to other studies that have
shown that trust in physicians and good experience with
the healthcare system may be reasons for volunteering
in research,24 31 the women in our study were dissatisﬁed
with the medical care for their menstrual pain, which
led them to participate in AKUD.
One may argue that, similar to other studies,21 24 31 the
women in our study participated in AKUD to achieve ben-
eﬁts both for themselves and for others. The women
articulated personal beneﬁts from participation as a motiv-
ation, but were clear that they also saw beneﬁts of trial par-
ticipation beyond themselves. The women had a clear
expectation that if the trial results were positive, their par-
ticipation would mean that women with menstrual pain
would receive the new treatment option through their phy-
sicians. Thus, they had a clear understanding that medical
practice is based on clinical trials and they expected clin-
ical trial results to be translated directly into medical prac-
tice. Unlike some other studies,17 19 none raised ideas of
moral duty for participation.
As McCann has argued, for actual participation per-
sonal beneﬁt is necessary, even though beneﬁt for
others is a reason to consider participation. This she
calls ‘conditional altruism’.23 In this context, one may
discuss ﬁnancial compensation. Paying participants
increases trial participation.7 15–17 However, it is contro-
versial as it may impede the idea of volunteerism,14 16
and also stands in contrast to the idea of participation as
a moral duty.19 The few studies conducted on research
participants’ views on ﬁnancial compensation have
mostly focused on healthy volunteers in phase 1 trials.14–
17 Although the women in our trial considered them-
selves healthy, their situation was quite different from
phase 1 volunteers. Healthy volunteers in general are
exposed to risk and discomfort, receiving in exchange
money or access to healthcare otherwise unavailable.14 17
Contrary to phase 1 trials, AKUD was a low risk trial
offering an unknown but promising therapeutic option
for a condition with a high impact on daily life. Some
have argued that in phase 1 trials, risks are downplayed
and ﬁnancial compensation may affect autonomy and
informed consent.14 16 Indeed, women in our study
argued that while compensation for trial participation is
appropriate, it should not be a wage. However, intervie-
wees were clear that research participants are autono-
mous individuals with the ability to make informed
decisions and to assess the potential risks and beneﬁts
for themselves, also when there is ﬁnancial
compensation.
Furthermore, while some respondents mentioned that
ﬁnancial compensation was important for them in decid-
ing on trial participation, it was not given by any as the
deciding factor. Taking into consideration the suggestion
of other authors that ﬁnancial motivation may not ini-
tially be mentioned because it is not perceived as socially
acceptable,32 the fact that the women in the incentive
group were older compared to those in the non-
incentive group nevertheless clearly suggests that the
recruitment rate for AKUD accelerated due to the
increase in the age limit.
Another point that may have been of importance in
the AKUD trial was the condition in question, namely
menstrual pain. Menstrual pain is difﬁcult to categorise
in the usual terms of ‘sick’ and ‘healthy’. Menstruation
is considered ‘natural’ and ‘normal’,33 but at the same
time some women experience severe menstrual pain or
other unpleasant symptoms. For instance, women in our
study reported the need to limit their activities and
reduce stress during menstruation, which impacted their
daily lives and could lead to occupational impair-
ment.34–36 For this ambivalent state, there exist no cul-
turally recognised strategies for menstruating women
outside of biomedicine and the existing biomedical
options were, for the women in our study, either inef-
fective or undesirable. This ambivalent state37 may be an
important reason why self-care approaches, such as the
one tested in AKUD, may be seen as a better option
than painkillers, as they are also considered ‘natural’.34
Regarding the limitations of our study, it should be
mentioned that our study sample was highly educated,
and one-third of interviewees mentioned having a
medical background. Furthermore, women who are satis-
ﬁed with the solutions offered by the medical system for
menstrual pain, mainly painkillers and oral contracep-
tives, had no reason to participate in the AKUD trial.
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This sampling bias is reﬂected in the small number of
women (n=7; 28%) in our sample taking oral contracep-
tives, compared to women aged 18–29 years in the
general population, of whom 72% take oral contracep-
tives.38 The presented results must therefore be inter-
preted with this in mind.
Our results contribute to the ongoing discussion of
whether ﬁnancial compensation of research participants
creates a risk of undue inducement. The women in our
study considered themselves and others capable of
adequately assessing risks and beneﬁts and thus of
making legitimately independent and voluntary choices.
The women were clear that while ﬁnancial compensa-
tion might have an impact on their decision-making
process, it would not affect their judgement about risk.
Finally, we suggest that the importance of clinical trials
providing new treatments that could change medical
practice might be an overlooked motivation for trial par-
ticipation that needs to be addressed in future recruit-
ment strategies.
Implication for practice
Our study ﬁndings indicate that recruitment strategies
should address the issue of the translation of study
results into clinical practice and the potentials and pit-
falls for shaping clinical practice through trial participa-
tion. A further point to address might be dissatisfaction
with available treatment options, especially in case of
‘normal’ conditions that have an impact on daily life
and for which biomedical treatments may not be the
ﬁrst or preferred choice for those affected, although
they might nevertheless ask their medical providers for
help. Opening up medical care for integrative
approaches for such conditions should be considered.
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